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In this issue of JACC: Heart Failure, Sandhu et al. Instead of commencing a new study, the CardioMEMS company, with FDA input, ended sponsor site communication and followed patients longer.
These additional follow-up data (collected after randomization had been revealed) led the company to conclude that the device's benefit persisted even without sponsor interaction with individual site physicians. However, the FDA commented that these follow-up analyses were ancillary because the followup study's success criteria were not defined a priori (15) . Although p values were provided for those new analyses, there was no attempt to adjust for the multiple comparisons and, thus, any statistically significant device-related benefits were not as rigorous as they would have been in the first (randomized) phase of the trial. Furthermore, at the time of review, 37% of the initially implanted patients had not continued in the study after the initial randomized period, and results for these patients were not included in the follow-up analyses. To summarize, the FDA stated, "it is difficult, at best, to accurately estimate how many HF-related hospitalizations were avoided by the nurse communications." After considering these data, the FDA's advisory panel harlan.krumholz@yale.edu.
